LIVOSTIN Drug Patent Profile

Which patents cover Livostin, and what generic alternatives are available?

Livostin is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in LIVOSTIN is levocabastine hydrochloride. There is one drug master file entry for this compound. Additional details are available on the levocabastine hydrochloride profile page.

Summary for LIVOSTIN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	47
Patent Applications:	640
DailyMed Link:	LIVOSTIN at DailyMed

US Patents and Regulatory Information for LIVOSTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	LIVOSTIN	levocabastine hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	020219-001	Nov 10, 1993		DISCN	No	No

Expired US Patents for LIVOSTIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	LIVOSTIN	levocabastine hydrochloride	SUSPENSION/DROPS;OPHTHALMIC	020219-001	Nov 10, 1993

International Patents for LIVOSTIN

See the table below for patents covering LIVOSTIN around the world.

Country	Patent Number	Title	Estimated Expiration
U.S.S.R.	1230467	"CПOCOБ ПOЛУЧEHИЯ ПPOИЗBOДHЫX 1-ЦИKЛOГEKCИЛ-4-APИЛ-4-ПИПEPИДИHKAPБOHOBЫX KИCЛOT,ИЛИ ИX KИCЛOTHO-AДДИTИBHЫX COЛEЙ,ИЛИ ИX CTEPEOXИMИЧECKИX ИЗOMEPHЫX ФOPM (EГO BAPИAHTЫ)" (METHOD OF PRODUCING 1-CYCLOHEXYL-4-ARYL-4-PIPERIDINCARBOXYLIC ACIDS DERIVATIVES OR THEIR STEREOCHEMICAL ISOMERIC FORMS (VERSIONS))
Portugal	72383	NOVEL 1-(CYCLOHEYL)-4-ARYL-J-PIPEDINECARBOXYLIC ACID DERIVATIVES
Slovenia	8110183	Novi derivati 1-(cikloheksil)-4-aril-4-piperidinkarboksilne kisline (PROCESS FOR OBTAINING NEW DERIVATIVES OF 1-(CYCLO-HEXYL)-4-ARYL-4-PIPERIDINE CARBOXYLIC ACID)
Denmark	157738
Bulgaria	35465	METHOD FOR PREPARING DERIVATIVES OF 1-(CYCLOHEXYL)-4-ARYL-4- PIPERIDINE CARBONIC ACID

Supplementary Protection Certificates for LIVOSTIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0034415	SPC/GB95/006	United Kingdom		SPC/GB95/006, EXPIRES: 20060110
0034415	93C0014	Belgium		PRODUCT NAME: LEVOCABASTINE HYDROCHLORIDE; NAT. REG.: 2S 400 F 11 19910604; FIRST REG.: DK 8252 19910111

LIVOSTIN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Livostin (Levocabastine)

Introduction

Livostin, marketed under the generic name levocabastine, is an ophthalmic medication primarily used to treat allergic conjunctivitis. This article delves into the market dynamics and financial trajectory of Livostin, exploring its benefits, market performance, and the broader pharmaceutical landscape.

Benefits and Uses of Livostin

Livostin is a targeted treatment for various allergy-related eye conditions, including seasonal and perennial allergic conjunctivitis. It provides relief from symptoms such as itchy, red, and watery eyes caused by allergens like pollen, pet dander, and dust mites[4].

Market Position and Competition

Livostin operates in the ophthalmic pharmaceutical market, which is highly competitive. The market is dominated by several key players, including companies like Santen Pharmaceutical and LivaNova, although these companies may not directly compete in the same niche as Livostin.

Market Share and Growth

While specific market share data for Livostin is not readily available, the ophthalmic pharmaceutical segment has seen steady growth. For instance, Santen Pharmaceutical's ophthalmic segment, which includes products like Cosopt and Tapros, has shown significant growth, indicating a robust market for ophthalmic medications[1].

Financial Performance

The financial performance of Livostin can be inferred from the broader trends in the ophthalmic pharmaceutical market.

Revenue Trends

Companies in the ophthalmic pharmaceutical sector often report steady revenue growth driven by the increasing demand for eye care treatments. For example, Santen Pharmaceutical's ophthalmic segment saw a 0.7% increase in sales in the third quarter of FY2012, with products like Diquas and Cosopt showing significant growth[1].

Cost and Pricing Dynamics

The pricing of ophthalmic medications can be influenced by various factors, including regulatory changes and market competition. A study on drug price dynamics highlights how price increases during the exclusivity period and decreases after the loss of exclusivity can impact cost-effectiveness analyses. This dynamic can affect the financial trajectory of drugs like Livostin, although specific data on Livostin's pricing is not available[3].

Sales and Distribution

Livostin is distributed through various channels, including pharmacies and healthcare providers. The sales strategy often involves targeted marketing to ophthalmologists and primary care physicians to increase prescription rates.

Regional Performance

The performance of ophthalmic medications can vary by region due to differences in healthcare systems, regulatory environments, and market demand. For instance, Santen Pharmaceutical's Asian business, particularly in China, has shown steady growth, indicating potential opportunities for Livostin in these markets[1].

Clinical Development and Innovation

While Livostin itself is an established product, the broader ophthalmic pharmaceutical market is driven by continuous innovation and clinical development. Companies like Santen Pharmaceutical and LivaNova invest heavily in research and development to bring new treatments to the market. This innovation can impact the competitive landscape and potentially influence the market position of existing products like Livostin[1][5].

Regulatory Environment

The regulatory environment plays a crucial role in the financial trajectory of pharmaceutical products. Changes in healthcare policies, reimbursement rates, and regulatory approvals can significantly impact sales and profitability. For example, the impact of the National Health Insurance (NHI) price revision in Japan affected the sales of various pharmaceutical products, including those in the ophthalmic segment[1].

Side Effects and Safety Profile

The safety profile of Livostin, including its side effects, can influence its market acceptance and financial performance. Common side effects include temporary relief of symptoms, but long-term use can lead to potential side effects and diminished effectiveness. This has led some patients to consider alternative treatments like allergy immunotherapy[4].

Market Outlook

The market outlook for Livostin is influenced by several factors, including the growing demand for ophthalmic treatments, competitive landscape, and regulatory environment.

Growing Demand for Ophthalmic Treatments

The increasing prevalence of eye allergies and other ophthalmic conditions drives the demand for treatments like Livostin. This trend is expected to continue, supporting the financial trajectory of the product.

Competitive Landscape

The competitive landscape in the ophthalmic pharmaceutical market is dynamic, with new products and treatments being introduced regularly. This competition can impact the market share and financial performance of Livostin.

Regulatory and Pricing Factors

Regulatory changes and pricing dynamics will continue to play a significant role in the financial trajectory of Livostin. Companies must navigate these factors to maintain profitability and market share.

Key Takeaways

• Market Position: Livostin operates in a competitive ophthalmic pharmaceutical market with steady growth trends.
• Financial Performance: The product's financial performance is influenced by broader market trends, regulatory changes, and pricing dynamics.
• Clinical Development: Continuous innovation in the ophthalmic sector can impact the competitive landscape and market position of Livostin.
• Regulatory Environment: Changes in healthcare policies and regulatory approvals significantly affect sales and profitability.
• Market Outlook: Growing demand for ophthalmic treatments and dynamic competitive landscape shape the future of Livostin.

FAQs

What is Livostin used for?

Livostin is used to treat allergic conjunctivitis, including seasonal and perennial allergic conjunctivitis, providing relief from symptoms like itchy, red, and watery eyes.

What are the common side effects of Livostin?

Common side effects include temporary relief of symptoms, but long-term use can lead to potential side effects and diminished effectiveness.

How does Livostin compare to other allergy treatments?

Livostin is a temporary relief medication, whereas allergy immunotherapy offers a more sustainable solution by desensitizing the body to allergens.

What factors influence the pricing of Livostin?

Pricing is influenced by regulatory changes, market competition, and the exclusivity period of the drug.

Is Livostin available globally?

Livostin is available in various regions, but its distribution and sales performance can vary due to differences in healthcare systems and market demand.

Sources

1. Santen Pharmaceutical: FY 2012 Third Quarter Results.
2. LivaNova: LivaNova Reports Second-Quarter 2024 Results.
3. PubMed: The Influence of US Drug Price Dynamics on Cost-Effectiveness Analyses.
4. Curex: Levocabastine (Livostin) Overview: Benefits, Side Effects.
5. LivaNova: LivaNova Reports Second-Quarter 2024 Results.